alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
AFS-10-356-E Aug 30 2010

Exemption No. 9775A Regulatory Docket No. FAA-2008-0994

Mr. Chuck Horgan

Director of Maintenance Center for Emergency Medicine of Western Pennyslvania, Inc.

STAT MedEvac 10 Allegheny County Airport West Mifflin, PA 15122

Dear Mr. Horgan:

This letter is to inform you that we have granted your petition to extend and amend Exemption No. 9775, as amended. It explains the basis for our decision and describes its

effect.

The Basis for Our Decision

By letter dated July 20, 2010, you petitioned the Federal Aviation Administration (FAA) on behalf of the Center for Emergency Medi cine, d/b/a STAT MedEvac (STAT) for an exemption from §§ 91.411(b) and 91.413(c) of Title 14, Code of Federal Regulations (14 CFR). The exemption, if granted, would allo w STAT to perform air traffic control (ATC) transponder tests and inspections and altimeter systems and altimeter reporting equipment tests and inspections for its part 135 aircraft maintained under an approved aircraft inspection program (AAIP). The amendment you request would remove the reference of a continuous aircraft maintenance program (CAMP) from the exemption, which erroneously appears in an earlier exemption.

In your petition, you indicate that there has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition in the Federal Register because the requested extension to the exemption would not set a precedent, and any delay in acting on this petition would be detrimental to STAT.2

Our Decision

The FAA has determined that the justification for the issuance of Exemption No. 9775, as amended, remains valid with respect to this exemption and is in the public interest. Therefore, under the authority provided by 49 U.S.C. 40113 and 44701, which the FAA Administrator has delegated to me, I grant your petition.

Conditions and Limitations

1. All ATC transponder tests and inspections and all altimeter reporting equipment tests and inspections must be conducted under STAT’s part 135 AAIP.

2. All tests and inspections must be recorded in the aircraft’s maintenance log by the person performing each inspection and test. This record must identify the person performing the inspection, the date of the inspection, and this exemption number.

3. All records of these tests and inspections also must be kept in STAT’s maintenance recording system for its part 135 aircraft.

The Effect of Our Decision

Our decision extends the termination date of Exemption No. 9775, as amended, to October 31, 2012, unless sooner superseded or rescinded. This letter must be attached to, and is a part of, Exemption No. 9775.

Sincerely,

/s/

John M. McGraw Acting Director, Flight Standard Service
#### § 822.12 Do you have any information that will help me prepare my submission or design my postmarket surveillance plan?

Guidance documents that discuss our current thinking on preparing a postmarket surveillance submission and designing a postmarket surveillance plan are available on the Center for Devices and Radiological Health's website, the Food and Drug Administration main website, and from the Food and Drug Administration, Center for Devices and Radiological Health, Office of Policy, Guidance and Policy Development, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. They do not establish legally enforceable rights or responsibilities and do not legally bind you or FDA. You may choose to use an approach other than the one set forth in a guidance document, as long as your alternative approach complies with the relevant statutes (laws) and regulations. If you wish, we will meet with you to discuss whether an alternative approach you are considering will satisfy the requirements of the act and regulations.

[75 FR 20915, Apr. 22, 2010, as amended at 87 FR 17950, Mar. 29, 2022]
##### 



Exhibit 4.31
 AMENDED
AND RESTATED EMPLOYMENT AGREEMENT
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT Agreement th Company Employee
 W I
T N E S S E T H:
  Employment
Agreement
   ARTICLE I
RESPONSIBILITIES
 Section
1.1 Scope of Employment.
 General. Parent Group
Company Group




---



##### 



Group Companies. Board
  Code UK Listing Authority
      2




---



##### 



ARTICLE II
COMPENSATION
 Section 2.1 General Terms.
 Base compensation.
 Bonus.
 Options.
  Section 2.2 Reimbursement
 3




---



##### 



Section 23 Employee Benefits.
 General
  Vacation Leave.
 ARTICLE III
NONDISCLOSURE OF CONFIDENTIAL INFORMATION
 Section 3.1 Definitions. Confidential Information prospective customers
 4




---



##### 



Section 3.2 Use and Disclosure.
 ARTICLE IV
NONCOMPETITION
 Section 4.1 Restriction. Relevant Group Company
 5




---



##### 



Section 4.2 Remedies
 Section 4.3 Reformation and Severance.
 ARTICLE V
TERM OF AGREEMENT
 Effective Date
 6




---



##### 



ARTICLE VI
TERMINATION
 Section 6.1 Termination.
 By Company Without Cause. Termination Without Cause Termination Date
 Severance Period
   Company Plans COBRA
 7




---



##### 



Successor Entity
 By Employee Without Cause.
 By
Company With Cause.
   8




---



##### 



Termination on Death.
 Termination on Disability.
 Obligations
on Termination.
   9




---



##### 



ARTICLE VII
ARBITRATION
 Section 7.1 Scope.
 Section 7.2 Procedures.
 10




---



##### 



Section 7.3 Enforcement
 ARTICLE VIII
ASSIGNMENT
 Section 8.1 Work Product
 Section 8.2
 11




---



##### 



ARTICLE IX
GENERAL TERMS
 Section 9.1 Notices
  
  
  
 Section 9.2
Withholding; No Offset
 Section 9.3 Entire Agreement; Modification.
 12




---



##### 



Section 9.4
Amendment.
 Section 9.5 Legal Consultation.
 Section 9.6 Choice of Law and Venue.
 Section 9.7 Successors and Assigns.
 Section 9.8 Waiver of Provisions.
 Section 9.9
Severability.
 Section 9.10 Counterparts.
   13




---



##### 



/s/ Saul Komisar
    
    
    

08th June, 2007Saul Komisar
    
    
    
    DateCOMPANYProtherics Inc.By:
    
    -s- Andrew J. Heath
    
    
    

7th
June, 2007Andrew J. Heath, M.D., Ph.D.,
    
    
    
    DateChief Executive Officer
 14
<PAGE>   1
                                                                    EXHIBIT 11.1


                                 MICROAGE, INC.
                         PRIMARY EPS DETAIL CALCULATION


<TABLE>
<CAPTION>
                                                            Quarters ended
                                                     ---------------------------
                                                     January 28,     January 29,
                                                         1996           1995
                                                     -----------     -----------
<S>                                                  <C>             <C>       
Common stock
-------------------------------
Weighted average common shares                        14,293,201      14,149,745

Common stock equivalents
-------------------------------
Weighted average warrants and options                     92,820         295,834
                                                     -----------     -----------

Total weighted average common and
       common equivalent shares outstanding           14,386,021      14,445,579
                                                     ===========     ===========

Net income available for EPS                         $ 1,557,000     $ 2,872,000

Primary EPS                                          $      0.11     $      0.20
</TABLE>
§ 600.10 Personnel. ( a ) [Reserved]
( b ) *Personnel.* Personnel shall have capabilities commensurate with their assigned functions, a thorough understanding of the manufacturing operations which they perform, the necessary training and experience relating to individual products, and adequate information concerning the application of the pertinent provisions of this subchapter to their respective functions. Personnel shall include such professionally trained persons as are necessary to insure the competent performance of all manufacturing processes.
( c ) *Restrictions on personnel* — ( 1 ) *Specific duties.* Persons whose presence can affect adversely the safety and purity of a product shall be excluded from the room where the manufacture of a product is in progress.
( 2 ) *Sterile operations.* Personnel performing sterile operations shall wear clean or sterilized protective clothing and devices to the extent necessary to protect the product from contamination.
( 3 ) *Pathogenic viruses and spore-forming organisms.* Persons working with viruses pathogenic for man or with spore-forming microorganisms, and persons engaged in the care of animals or animal quarters, shall be excluded from areas where other products are manufactured, or such persons shall change outer clothing, including shoes, or wear protective covering prior to entering such areas.
( 4 ) *Live vaccine work areas.* Persons may not enter a live vaccine processing area after having worked with other infectious agents in any other laboratory during the same working day. Only persons actually concerned with propagation of the culture, production of the vaccine, and unit maintenance, shall be allowed in live vaccine processing areas when active work is in progress. Casual visitors shall be excluded from such units at all times and all others having business in such areas shall be admitted only under supervision. Street clothing, including shoes, shall be replaced or covered by suitable laboratory clothing before entering a live vaccine processing unit. Persons caring for animals used in the manufacture of live vaccines shall be excluded from other animal quarters and from contact with other animals during the same working day.
[38 FR 32048, Nov. 20, 1973, as amended at 49 FR 23833, June 8, 1984; 55 FR 11014, Mar. 26, 1990; 62 FR 53538, Oct. 15, 1997; 68 FR 75119, Dec. 30, 2003]
§ 573.940 Silicon dioxide. The food additive silicon dioxide may be safely used in animal feed in accordance with the following conditions: ( a ) The food additive is manufactured by vapor phase hydrolysis or by other means whereby the particle size is such as to accomplish the intended effect.
( b ) It is used or intended for use as an anticaking agent, antifoaming agent, carrier, and/or grinding aid in animal feed, including ingredients, intermediate premixes, premixes, supplements, concentrates, and complete feed.
( c ) To ensure safe use of the additive, silicon dioxide is to be used in an amount not to exceed that reasonably required to accomplish its intended effect, and silicon dioxide from all sources cannot exceed 2 percent by weight of the complete feed.
( d ) To ensure safe use of the additive, the label and labeling of the additive and ingredients, intermediate premixes, premixes, supplements, concentrates, and complete feed containing the additive shall meet the requirements of the Federal Food, Drug, and Cosmetic Act, including part 501 of this chapter.
( e ) To ensure safe use of the additive, in addition to the other information required by the Federal Food, Drug, and Cosmetic Act, the label and labeling of the additive and ingredients, intermediate premixes, premixes, supplements, and concentrates containing the additive shall have: ( 1 ) A statement of the concentration of the additive.
( 2 ) A statement that silicon dioxide from all sources cannot exceed 2 percent by weight of the complete feed.
[41 FR 38652, Sept. 10, 1976, as amended at 83 FR 8930, Mar. 2, 2018; 84 FR 7993, Mar. 6, 2019; 85 FR 33539, June 2, 2020]
Exhibit
13.1
  Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of Section 1350, Chapter 63 of Title 18, United States Code), each
of the undersigned officers of Deutsche Telekom AG (the “Company”), does hereby
certify, to such officer’s knowledge, that:
  The
Annual Report on Form 20-F for the year ended December 31, 2008 (the
“Form 20-F”), of the Company fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
information contained in the Form 20-F fairly presents, in all material
respects, the financial condition and results of operations of the
Company.
  Date:
      February 27, 2009
                
                /s/ René
      ObermannRené
      ObermannChairman
      of the Management BoardDated:
      February 27, 2009
                
                /s/Dr. Karl-Gerhard
      EickDr. Karl-Gerhard
      EickDeputy
      Chairman of the Management Board
Finance
Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report on Form 10-KSB ("Form 10-KSB") of Smart-tek

Solutions, Inc. (the "Company") for the annual period ended June 30,2006 as filed with

the Securities and Exchange Commission on the date hereof, I, Perry Law, Chief Executive

Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant

to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1)   The Form 10-KSB fully complies with the requirements of Section

13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)   The information contained in the Form 10-KSB fairly presents, in all

material respects, the financial condition and results of operations

of the Company.



/s/ Perry Law

---------------------------

Perry Law

Chief Executive Officer

October 11, 2006
§ 520.2604 Trimeprazine and prednisolone tablets. ( a ) *Specifications.* Each tablet contains 5 milligrams (mg) trimeprazine tartrate and 2 mg prednisolone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally an initial dosage: for dogs weighing up to 10 pounds, 1 ⁄ 2 tablet twice daily; for dogs weighing 11 to 20 pounds, 1 tablet twice daily; for dogs weighing 21 to 40 pounds, 2 tablets twice daily; and for dogs weighing over 40 pounds, 3 tablets twice daily. After 4 days, reduce dosage to one-half the initial dose or to an amount sufficient to maintain remission of symptoms.
( 2 ) *Indications for use.* For the relief of itching regardless of cause; and for reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, allergic, parasitic, pustular, and nonspecific origins. As adjunctive therapy in various cough conditions including treatment of “kennel cough” or tracheobronchitis, bronchitis including allergic bronchitis, infections, and coughs of nonspecific origin.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28833, May 20, 2014, as amended at 87 FR 10969, Feb. 28, 2022]
```

[Federal Register Volume 78, Number 129 (Friday, July 5, 2013)]
[Notices]
[Page 40544]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16155]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 8372]

Culturally Significant Objects Imported for Exhibition 
Determinations: ``New Photography 2013: Adam Broomberg and Oliver 
Chanarin, Brendan Fowler, Annette Kelm, Lisa Oppenheim, Anna Ostoya, 
Josephine Pryde, and Eileen Quinlan''

SUMMARY: Notice is hereby given of the following determinations: 
Pursuant to the authority vested in me by the Act of October 19, 1965 
(79 Stat. 985; 22 U.S.C. 2459), Executive Order 12047 of March 27, 
1978, the Foreign Affairs Reform and Restructuring Act of 1998 (112 
Stat. 2681, et seq.; 22 U.S.C. 6501 note, et seq.), Delegation of 
Authority No. 234 of October 1, 1999, Delegation of Authority No. 236-3 
of August 28, 2000 (and, as appropriate, Delegation of Authority No. 
257 of April 15, 2003), I hereby determine that the objects to be 
included in the exhibition ``New Photography 2013: Adam Broomberg and 
Oliver Chanarin, Brendan Fowler, Annette Kelm, Lisa Oppenheim, Anna 
Ostoya, Josephine Pryde, and Eileen Quinlan,'' imported from abroad for 
temporary exhibition within the United States, are of cultural 
significance. The objects are imported pursuant to loan agreements with 
the foreign owners or custodians. I also determine that the exhibition 
or display of the exhibit objects at The Museum of Modern Art, New 
York, NY, from on or about September 14, 2013, until on or about 
February 5, 2014, and at possible additional exhibitions or venues yet 
to be determined, is in the national interest. I have ordered that 
Public Notice of these Determinations be published in the Federal 
Register.

FOR FURTHER INFORMATION CONTACT: For further information, including a 
list of the exhibit objects, contact Julie Simpson, Attorney-Adviser, 
Office of the Legal Adviser, U.S. Department of State (telephone: 202-
632-6467). The mailing address is U.S. Department of State, SA-5, L/PD, 
Fifth Floor (Suite 5H03), Washington, DC 20522-0505.

    Dated: June 27, 2013.
J. Adam Ereli,
Principal Deputy Assistant Secretary, Bureau of Educational and 
Cultural Affairs, Department of State.
[FR Doc. 2013-16155 Filed 7-3-13; 8:45 am]
BILLING CODE 4710-05-P
```
# C_2015007EN.01005702.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/57 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/57

---

Action brought on 27 October 2014 — ZZ v Council

(Case F-121/14)

(2015/C 007/73)

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: L. Levi and N. Flandin, lawyers)

Applicant:

Defendant: Council

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the Council decision to apply a solidarity levy, as from 1 January 2014, to the applicant’s remuneration and not to adjust his remuneration for the period from 1 January 2014 to 30 June 2015.

Form of order sought

Form of order sought

| — | Annul the express decision applying a solidarity levy from 1 January 2014 to 30 June 2015 even though there is a remuneration adjustment freeze covering the period from 1 January 2014 to 30 June 2015 and, |
| --- | --- |

—

Annul the express decision applying a solidarity levy from 1 January 2014 to 30 June 2015 even though there is a remuneration adjustment freeze covering the period from 1 January 2014 to 30 June 2015 and,

| — | annul the implied decision not to apply an annual adjustment of the applicant’s remuneration for the period from 1 January 2014 to 30 June 2015, those two decisions having been disclosed for the first time in the applicant’s payslip for January 2014 and notified on 14 January 2014; |
| --- | --- |

—

annul the implied decision not to apply an annual adjustment of the applicant’s remuneration for the period from 1 January 2014 to 30 June 2015, those two decisions having been disclosed for the first time in the applicant’s payslip for January 2014 and notified on 14 January 2014;

| — | in so far as necessary, annul the decision of 17 July 2014 rejecting the complaint; |
| --- | --- |

—

in so far as necessary, annul the decision of 17 July 2014 rejecting the complaint;

| — | order the Council to pay all the costs. |
| --- | --- |

—

order the Council to pay all the costs.

---
---

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Smart-tek Solutions,
Inc., (the "Company") on Form 10KT/A Amendment No. 2 for the six month period
ending December 31, 2010 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, Brian Bonar, Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec.
906 of the Sarbanes-Oxley Act of 2002, that to the best of the undersigneds
knowledge and belief:

(1)      The Report fully
complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and

(2)      The information contained in
the Report fairly presents, in all material respects, the financial condition
and result of operations of the Company.

/s/ Brian Bonar Brian Bonar Chief Financial
Officer

September 9, 2011

---
§ 522.960a Flumethasone suspension. ( a ) *Specifications.* Each milliliter of suspension contains 2 milligrams (mg) of flumethasone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 6 to 10 mg by intra-articular injection. Dosage is limited to a single injection per week in any one synovial structure.
( 2 ) *Indications for use.* For use in the various disease states involving synovial structures (joints) of horses where excessive synovial fluid of inflammatory origin is present and where permanent structural changes do not exist. Such conditions include arthritis, carpitis, and osselets.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16188, Mar. 25, 2014]
§ 522.275 N-Butylscopolammonium. ( a ) *Specifications.* Each milliliter of solution contains 20 milligrams (mg) N-butylscopolammonium bromide.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 0.3 mg per kilogram of body weight (0.14 mg per pound) slowly intravenously.
( 2 ) *Indications for use.* For the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[69 FR 35512, June 25, 2004]
#### § 58.10 Applicability to studies performed under grants and contracts.

When a sponsor conducting a nonclinical laboratory study intended to be submitted to or reviewed by the Food and Drug Administration utilizes the services of a consulting laboratory, contractor, or grantee to perform an analysis or other service, it shall notify the consulting laboratory, contractor, or grantee that the service is part of a nonclinical laboratory study that must be conducted in compliance with the provisions of this part.
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7900 Thromboplastin generation test. ( a ) *Identification.* A thromboplastin generation test is a device used to detect and identify coagulation factor deficiencies and coagulation inhibitors.
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60628, Sept. 12, 1980, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38790, July 25, 2001]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1635 Total protein test system. ( a ) *Identification.* A total protein test system is a device intended to measure total protein(s) in serum or plasma. Measurements obtained by this device are used in the diagnosis and treatment of a variety of diseases involving the liver, kidney, or bone marrow as well as other metabolic or nutritional disorders.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 63 FR 59225, Nov. 3, 1998]